Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Houston-based cell biology firm Stem Cell Innovations is set to commercialize its proprietary platform of human pluripotent stem cells in Europe through its newly established R&D facility in the Netherlands.
Subscribe to our email newsletter
The company operates to give pharmaceutical & biotech companies a toxicity testing platform to assist them in streamlining their development pipeline by selecting the right molecules early in the process for further development.
Stem Cell Innovations (SCI) has produced multiple lines of human pluripotent stem cells. These cell lines are able to maintain their undifferentiated state and normal chromosome complement. The cells are produced without feeder layers (xenofree).
The company says it is able to efficiently develop multiple lines, the first step in creating banks of cells that can be matched to patients in cell therapies.
To be able to serve the European market and to make the cells available to both scientists in academia and the European pharma and biotech industry, SCI will produce stem cell lines in Leiden, Netherlands as well as in Houston, Texas.